Anaptysbio, Inc. · NASDAQ:ANAB
Anaptysbio — Technical Presentation (September 2018)
15 slides from Anaptysbio's technical presentation, Sep 24, 2018
Slide 1: Etokimab (Anti-IL-33) Program: Phase 2a Eosinophilic Asthma Interim Data Update
Exhibit 99.2 Etokimab (Anti-IL-33) Program Phase 2a Eosinophilic Asthma Clinical Trial Interim Data Update th September 24 2018 Nasdaq: ANAB
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation and the accompanying oral presentation contain “forward-looking” statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing of the release of data from our cl
Slide 3: AnaptysBio: Clinical-Stage Antibody Development Company
AnaptysBio: Clinical-Stage Antibody Development Company Focused on Novel Antibody Medicines for Severe Inflammatory Diseases Wholly-Owned Rapid Antibody Generation Anti-Inflammatory Pipeline Platform Technology Etokimab (ANB020, Anti-IL-33) Atopic Dermatitis, Eosinophilic Asthma & Chronic Rhinosinus
Slide 4: Wholly-Owned and Partnered Product Pipeline
Wholly-Owned and Partnered Product Pipeline 6 AnaptysBio-Generated Antibodies Advanced to Clinic Since Q1 2016 All programs generated internally using AnaptysBio’s proprietary antibody generation platform technology 4
Slide 5: Etokimab: First-in-Class Anti-IL-33 Antibody
Etokimab: First-in-Class Anti-IL-33 Antibody Broadly Applicable to Atopic Diseases • IL-33 is an upstream driver of atopic disease – Human genetics validate key role of IL-33 in atopic dermatitis and asthma – Pro-inflammatory cytokine released upon allergen contact with epithelium – Activates downst
Slide 6: Eosinophilic Asthma
Eosinophilic Asthma Focus on Severe Patients Inadequately Controlled With ICS/LABA • Eosinophilic asthma is a debilitating, chronic atopic disease - Decreased lung function associated with poor quality-of-life and exacerbations - Often concomitant with other atopic diseases, such as chronic rhinosin
Slide 7: Etokimab Clinical Trials
Etokimab Clinical Trials Key Clinical Subjects Trial TrialDesign Timing Endpoint(s) n=96, SAD and MAD cohorts, IV Top-line data announced October 2016 Healthy Volunteers Phase 1 and SC dosing, randomized, Safety, PK and PD Detailed data presented at AAD and AAAAI 2017 placebo-controlled EczemaArea &
Slide 8: Etokimab Eosinophilic Asthma Phase 2a Trial
Etokimab Eosinophilic Asthma Phase 2a Trial Single Dose of Etokimab or Placebo Administered on Day 1 Etokimab300mg IV Single Dose + High Dose ICS/LABA n=12 Placebo Single Dose + High Dose ICS/LABA n=13 Adults with severe asthma (according to GINA 2016) Pre-bronchodilator FEV1 <80% of predicted Patie
Slide 9: Key Baseline Parameters
Key Baseline Parameters Average Baseline Parameters of Etokimab Arm PlaceboArm EnrolledPatients(Day 1 Pre-Dose) n 12 13 BloodEosinophils 545 705 per microliter FEV1(Liters) 2.5 2.5 % PredictedFEV1 65% 66% Age (years) 41 36 Male % 75% (9 of 12) 69% (9of 13) 9
Slide 10: % FEV1 Improvement Relative to Baseline After Single Dose
% FEV1 Improvement Relative to Baseline After Single Dose Rapid and Sustained FEV1 Improvement Post-Etokimab Administration Timepoint Etokimab Placebo Net Day 1 0% 0% 0% (Baseline) Day 2 12% 4% 8% Day 8 9% 5% 4% Day 22 16% 8% 8% Day 36 14% 8% 6% Day 64 15% 4% 11% 10
Slide 11: Blood Eosinophil Reduction Relative to Baseline After Single Dose
Blood Eosinophil Reduction Relative to Baseline After Single Dose Correlates with FEV1 Improvement and Consistent With Phase 2a Atopic Dermatitis Trial Timepoint Etokimab Placebo Net Day 1 0% 0% 0% (Baseline) Day 2 -22% 9% -31% Day 8 -34% -15% -19% Day 22 -30% -10% -20% Day 36 -43% 1% -44% Day 64 -4
Slide 12: Eosinophilic Asthma Phase 2a Day 64 Interim Analysis
Eosinophilic Asthma Phase 2a Day 64 Interim Analysis Supports Advancement of Etokimab Into Phase 2b Eosinophilic Asthma Trial Interim Analysis Summary • Etokimab demonstrated proof-of-concept in eosinophilic asthma • Single dose of etokimab resulted in rapid and sustained improvement in FEV1 over pl
Slide 13: Anticipated Milestones
Anticipated Milestones 4 Additional Efficacy Readouts Anticipated By End 2019 Program Milestone Timing Moderate-to-Severe Adult Top-line data announced October 2017 Atopic Dermatitis Phase 2a Trial Detailed data presented at AAD and EAACI 2018 ATLAS: Moderate-to-Severe Adult Initiated H1 2018 Atopic
Slide 14: AnaptysBio: Clinical-Stage Antibody Development Company
AnaptysBio: Clinical-Stage Antibody Development Company Focused on Novel Antibody Medicines for Severe Inflammatory Diseases Wholly-Owned Rapid Antibody Generation Anti-Inflammatory Pipeline Platform Technology Etokimab (ANB020, Anti-IL-33) Atopic Dermatitis, Eosinophilic Asthma & Chronic Rhinosinus
Slide 15: AnaptysBio
AnaptysBioW